Literature DB >> 26443430

Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.

Justin C Voog1, Rebecca Paulus2, Jason A Efstathiou3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26443430      PMCID： PMC4893789          DOI： 10.1016/j.eururo.2015.09.030

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  8 in total

1.  Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome?

Authors:  Ronald C Chen
Journal:  Eur Urol       Date:  2015-09-26       Impact factor: 20.096

2.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

3.  Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Xin Pei; Yoshiya Yamada; Abraham Kalikstein; Deborah Kuk; Zhigang Zhang; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-14       Impact factor: 7.038

4.  The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease.

Authors:  Florence K Keane; Ming-Hui Chen; Danjie Zhang; Marian J Loffredo; Philip W Kantoff; Andrew A Renshaw; Anthony V D'Amico
Journal:  Cancer       Date:  2014-03-06       Impact factor: 6.860

5.  Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Authors:  Ann C Raldow; Danjie Zhang; Ming-Hui Chen; Michelle H Braccioforte; Brian J Moran; Anthony V D'Amico
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

6.  A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Isaac Pei; Zhigang Zhang; Yoshiya Yamada; Marisa Kollmeier; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-03-23       Impact factor: 20.096

7.  Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.

Authors:  Richard K Valicenti; Kwounghwa Bae; Jeff Michalski; Howard Sandler; William Shipley; Alex Lin; James Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

8.  Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Authors:  Justin C Voog; Rebecca Paulus; William U Shipley; Matthew R Smith; David G McGowan; Christopher U Jones; Jean-Paul Bahary; Kenneth L Zeitzer; Luis Souhami; Mark H Leibenhaut; Marvin Rotman; Siraj M Husain; Elizabeth Gore; Adam Raben; Susan Chafe; Howard M Sandler; Jason A Efstathiou
Journal:  Eur Urol       Date:  2015-09-09       Impact factor: 20.096
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.